Abstract：Objective To investigate the role of endogenous vascular elastase (EVE) in coronary artery between reconstruction among pediatric patients with Kawasaki disease (KD). Methods Sixty children who were diagnosed with KD between January 2012 and April 2013 were selected as the case group, and peripheral venous blood samples were collected on days 0-11 (pathological stage I) and days 12-25 (pathological stage Ⅱ) after the onset of disease; another 60 children without KD who visited the hospital due to acute fever during the same period were selected as the control group, and fasting peripheral venous blood samples were collected in the acute stage of fever. For both groups, serum levels of EVE and interleukin-6 (IL-6) and plasma vascular endothelial growth factor (VEGF) level were measured by enzyme-linked immunosorbent assay. For the case group, ultrasonic cardiography was used to detect coronary artery lesions (CALs) at the first, second and fourth weekends. The correlations of EVE level with IL-6 and VEGF levels were evaluated by Pearson correlation analysis. Results Serum levels of EVE and IL-6 in the case group in pathological stages I and Ⅱ were significantly higher than in the control group (PPPPPr=0.915, Pr=-0.769, PConclusions EVE may participate in coronary artery reconstruction in children with KD. To interfere EVE activity may reduce and prevent CALs.
LIU Yi-Ling,WANG Xian-Min,LI Yan et al. The role of endogenous vascular elastase in coronary artery reconstruction in Kawasaki disease[J]. CJCP, 2014, 16(4): 389-392.
Chappell JC, Bautch VL. Vascular development: genetic mechanisms and links to vascular disease[J]. Curr Top Dev Biol, 2010, 90: 43-72.
[5]
Kurtagic E, Jedrychowski MP, Nugent MA. Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity[J]. Am J Physiol Lung Cell Mol Physiol, 2009, 296(3): L534-L546.
[6]
Tan Z, Yuan Y, Chen S, et al. Plasma endothelial microparticles, TNF-α and IL-6 in Kawasaki disease[J]. Indian Pediatr, 2013, 50(5): 501-503.
[7]
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Circulation, 2004, 110(17): 2747-2771.
[8]
Coustasse A, Larry J, Lee D. Can Kawasaki disease be managed?[J]. Perm J, 2012, 16(2): 70-72.
Lv YW, Wang J, Sun L, et al. Understanding the pathogenesis of Kawasaki disease by network and pathway analysis[J]. Comput Math Methods Med, 2013, 2013: 989307.
[11]
Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation[J]. Cold Spring Harb Perspect Med, 2012, 2(2): a006544.
Rabinovitch M. Pathobiology of pulmonary hypertension: Impact on clinical management[J]. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, 2000, 3: 63-81.
[16]
Sotelo-Cruz N. A review of Kawasaki disease, a perspective from the articles published in Mexico since January 1977 to May 2012[J]. Arch Cardiol Mex, 2013, 83(3): 214-222.
